Evidence map›Paper›PMID 38794309›Full record

ArticlePharmaceutics2024

Effect of Antioxidants in Medicinal Products on Intestinal Drug Transporters.

Chetan P Kulkarni, Jia Yang, Megan L Koleske, Giovanni Lara, Khondoker Alam, Andre Raw, Bhagwant Rege, Liang Zhao, Dongmei Lu, Lei Zhang and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Chetan P KulkarniDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA 94158, USA.
Jia YangDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA 94158, USA.ORCID 0000-0002-3992-4070
Megan L KoleskeDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA 94158, USA.
Giovanni LaraDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA 94158, USA.
Khondoker AlamOffice of Generic Drugs, Center for Drug Evaluation and Research, FDA, Silver Spring, MD 20993, USA.
Andre RawOffice of Pharmaceutical Quality, Center for Drug Evaluation and Research, FDA, Silver Spring, MD 20993, USA.
Bhagwant RegeOffice of Pharmaceutical Quality, Center for Drug Evaluation and Research, FDA, Silver Spring, MD 20993, USA.
Liang ZhaoOffice of Generic Drugs, Center for Drug Evaluation and Research, FDA, Silver Spring, MD 20993, USA.
Dongmei LuOffice of Pharmaceutical Quality, Center for Drug Evaluation and Research, FDA, Silver Spring, MD 20993, USA.
Lei ZhangOffice of Generic Drugs, Center for Drug Evaluation and Research, FDA, Silver Spring, MD 20993, USA.
Lawrence X YuOffice of Pharmaceutical Quality, Center for Drug Evaluation and Research, FDA, Silver Spring, MD 20993, USA.
Robert A LionbergerOffice of Generic Drugs, Center for Drug Evaluation and Research, FDA, Silver Spring, MD 20993, USA.
Kathleen M GiacominiDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA 94158, USA.
Deanna L KroetzDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA 94158, USA.ORCID 0000-0001-5997-270X
Sook Wah YeeDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA 94158, USA.ORCID 0000-0001-8121-8746

Funding

UCSF-Stanford Center of Excellence in Regulatory Science and InnovationU01FD005978 · FDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ALTMAN, RUSS BIAGIO, GIACOMINI, KATHLEEN M · 2016 to 2025
$34.5M
FDA HHS U01 FD005978United States Food and Drug Administration U01FD005978
6 · The paper itself

Abstract

The presence of mutagenic and carcinogenic N-nitrosamine impurities in medicinal products poses a safety risk. While incorporating antioxidants in formulations is a potential mitigation strategy, concerns arise regarding their interference with drug absorption by inhibiting intestinal drug transporters. Our study screened thirty antioxidants for inhibitory effects on key intestinal transporters-OATP2B1, P-gp, and BCRP in HEK-293 cells (OATP2B1) or membrane vesicles (P-gp, BCRP) using

Indexed as

antioxidantsBCRPintestinal transportersnitrosamineOATP2B1P-gp

Identifiers

PMID38794309
PMCPMC11124870

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.